Ann has over 35 years experience in Drug Discovery and Development in the Pharmaceutical industry.

Chief Operating Officer and Co-Founder

Ann Lewis has over 35 years experience in Drug Discovery and Development in the pharmaceutical industry and has co-authored 16 scientific publications.

Beginning her career at Weddel Pharmaceuticals and progressing to more senior roles at SK&F and then SmithKline Beecham, Ann became a section head within Preclinical Discovery where she held responsibility for drug metabolism and pharmacokinetic (DMPK) data in support of Target-to-Lead and Lead-to-Candidate packages for projects in the neuroscience, pain, GI and cardiovascular disease areas.

Following the SB/Glaxo merger in 2000, Ann became Head of DMPK Operations and Outsourcing within GSK’s Neurology Centre of Excellence for Drug Discovery, successfully building a flexible and cost-effective outsourced capability. 

In 2011 she joined the biotech Cellzome as a DMPK consultant where she integrated internal Project Teams and external CROs to drive compound progression towards Candidate Selection.

Since 2013 Ann has successfully delivered several client-based drug discovery assignments through Xenovium and continues to coordinate all business administration activities.

Novel Immunomodulator – Preclinical to Clinical Development
Discover how we supported a virtual biotech both strategically and operationally to ensure were best positioned for future fund-raising discussions…
Contact Us
  • Xenovium Ltd,
    Chesterford Research Park, Little Chesterford, Saffron Walden, CB10 1XL